 Akers Biosciences, Inc. the Company AKER, a developer of rapid health information technologies, today announced with its partner, Premas Biotech, the initiation of animal studies for its SARS-CoV-2 vaccine candidate in India. Premas has successfully completed the manufacturing process for the VLP virus like particle vaccine candidate, including three antigens from SARS-CoV-2. Premas plans to administer the test across different dose amounts, including amounts that would be applicable to humans. 